In the recently held Pegasys B individual treatment session, Chinese Medical Association chairman of the society of infectious diseases, Dep
In the recently held Pegasys B individual treatment session, Chinese Medical Association chairman of the society of infectious diseases, Department of infectious diseases Huashan Hospital Affiliated to Fudan University Professor Professor Weng Xinhua believes that young patients with hepatitis B should be the first choice of interferon therapy. Because taking nucleoside analogues drugs, only a simple inhibition of viral replication, but can not stimulate the body's own immunity, it is difficult to avoid the withdrawal of the recurrence of the consequences. While the use of interferon treatment, after one year 42% of the "big 3 this world" to "small Sanyang", even clinical cure is possible.
According to the 2008 National Population Health Ministry announced the hepatitis B epidemiological investigation showed that hepatitis B virus carrying rate of 7.18% in China, there are currently 93 million carriers of hepatitis B virus, which is 1/4 patients will develop chronic liver disease, some patients may develop cirrhosis and liver cancer. Unfortunately, our hepatitis B patients have poor ability to clear the virus. The Beijing Liberation Army No.302 Hospital department chief physician professor Zhang Hongfei pointed out that "China's hepatitis B patients mostly because of infant transmission and infection, because the virus infection in the womb, their ability to clear the virus in these patients, 70%-80% are refractory hepatitis b."
It is not enough to suppress viral replication in patients with refractory hepatitis B. Zhang Hongfei said that the long-term use of nucleoside analogues inhibit viral replication, on the one hand, may stop on relapse, on the other hand, the virus may produce resistance variation, resulting in hepatitis B recurrence or deterioration of the disease. Interferon can stimulate the body's immune system, mobilize the body to fight against the virus. According to the clinical data show that after the use of interferon for a year, there is a 42% chance to achieve "big Sanyang" to "small Sanyang", and to realize the "U" (surface antigen) negative clinical cure. So, for the young and ready to have hepatitis B patients, should be the first choice of interferon treatment, direct antiviral and stimulate human immunity, reduce the incidence of liver cirrhosis and hepatocellular carcinoma, and prolong the survival time of the patients.